59 related articles for article (PubMed ID: 38675482)
1. Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®.
Laveille C; Snoeck E; Ochoa Díaz de Monasterioguren L; Martínez-González J; Llaudó J; Anta L; Gutierro I
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38866397
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
Falcão A; Fuseau E; Nunes T; Almeida L; Soares-da-Silva P
CNS Drugs; 2012 Jan; 26(1):79-91. PubMed ID: 22171585
[TBL] [Abstract][Full Text] [Related]
4. A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.
Jiang X; Yu KS; Nam DH; Oh J
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675482
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
Riggs MM; Staab A; Seman L; MacGregor TR; Bergsma TT; Gastonguay MR; Macha S
J Clin Pharmacol; 2013 Oct; 53(10):1028-38. PubMed ID: 23940010
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
7. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation.
Sheng W; Yu J; Zhang H; Zhang J
Mol Immunol; 2024 Mar; 167():43-52. PubMed ID: 38354482
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis.
Lv C; Hu C; Zhu C; Wan X; Chen C; Ji X; Qin Y; Lu L; Guo X
Biomed Pharmacother; 2024 Jan; 170():115963. PubMed ID: 38042114
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes.
Hierro-Bujalance C; Garcia-Alloza M
Neural Regen Res; 2024 Jun; 19(6):1189-1190. PubMed ID: 37905858
[No Abstract] [Full Text] [Related]
12. Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects.
Jiang X; Bae S; Yoon DY; Park SJ; Oh J; Cho JY; Yu KS
Drug Des Devel Ther; 2023; 17():2137-2145. PubMed ID: 37521035
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Empagliflozin L-Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects.
Lee H; Chung JY; Yu KS; Park SJ; Lee S
Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1156-1163. PubMed ID: 37489552
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
